Every 10-Q that SAB Biotherapeutics, Inc. (SABS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow SABS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SABS filings page.
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing multi-specific human IgG therapies, reported higher operating spending and net losses for the quarter ended June 30, 2026 while strengthening its capital base. The company’s lead asset, SAB-142, is in a registrational Phase 2b SAFEGUARD trial in newly diagnosed Stage 3 type 1 diabetes.
Total operating expenses for Q2 2026 were $23,377 (in thousands), driven by research and development of $16,172 (in thousands) and general and administrative of $7,205 (in thousands). Net loss for the quarter was $22,491 (in thousands), and for the first six months of 2026 it was $41,360 (in thousands), or $0.62 basic and diluted loss per share.
As of June 30, 2026, the company held cash and cash equivalents of $8,267 (in thousands), short-term investments of $94,365 (in thousands), and long-term investments of $105,346 (in thousands), supporting total assets of $238,210 (in thousands) and stockholders’ equity of $214,785 (in thousands). A March 2026 public offering of common stock and pre-funded warrants generated net proceeds of approximately $88,697 (in thousands). Based on its current operating expense level, management states existing resources are expected to cover operating cash needs for at least twelve months following the report date.
SAB Biotherapeutics, Inc. reported a larger net loss for the three months ended March 31, 2026 as it increased investment in its pipeline. Net loss was $18,868,885, compared with $5,196,773 a year earlier, driven by higher research and development expenses of $13,397,977 and general and administrative costs of $6,599,759.
The company strengthened its balance sheet with a March 2026 public offering of common stock and pre-funded warrants, generating approximately $86.4 million in net proceeds. Cash and cash equivalents were $20,519,724, with short-term investments of $86,871,857 and long-term investments of $110,235,540, bringing total assets to $248,470,498.
Operating cash outflow was $14,271,130 for the quarter. Management notes an accumulated deficit of $129,764,052 and expects to continue incurring losses but believes current resources will cover operating cash needs for at least twelve months. Common shares outstanding were 75,744,576 as of March 31, 2026.
SAB Biotherapeutics, Inc. reported Q3 results showing a swing to net income, driven by non‑cash warrant valuation effects and a mid‑year capital raise. For the quarter, the company recorded net income of $45.4 million, while operating activities remained in investment mode with loss from operations of $12.7 million as R&D and G&A totaled $12.7 million. No revenue was recognized in the period.
The balance sheet strengthened markedly. As of September 30, 2025, cash and cash equivalents were $29.4 million, with short‑term investments of $81.5 million and long‑term investments of $50.6 million. Total assets rose to $183.4 million and stockholders’ equity to $165.1 million, reflecting proceeds from the 2025 private placement and equity reclassifications. The quarter included a $61.6 million gain from changes in fair value of warrant liabilities and $4.9 million of warrant issuance costs.
Year to date, net cash used in operations was $28.0 million, offset by $168.7 million provided by financing activities from the 2025 PIPE. The company noted existing resources are sufficient to cover operating cash needs for the twelve months following the report date. Common shares outstanding were 47,606,851 as of November 10, 2025.